Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs 10X Genomics Inc (TXG) Price & Performance

Citius Pharmaceuticals IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs 10X Genomics Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while 10X Genomics Inc trades at $59.24 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 380.3× Citius Pharmaceuticals Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRTXG
Market Cap
$20.01M$7.61B
Sector
HealthHealth
52-Week High
$1.82$58.57
52-Week Low
$0.48$11.34
Enterprise Value
$16.23M$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

10X Genomics Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG